The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press1910.17650/1818-8338-2013-3-4-98-103PHARMACOTHERAPYФАРМАКОТЕРАПИЯANTIBIOTIC THERAPY FOR ENT INFECTIONSАНТИБАКТЕРИАЛЬНАЯ ТЕРАПИЯ ИНФЕКЦИЙ ЛОР-ОРГАНОВTurovskyA. B.ТуровскийА. Б.
Russian Federation
mnpco@mosgorzdrav.ruKaryukYu. A.КарюкЮ. А.
Russian Federation
KondrashinaV. V.КондрашинаВ. В.
Russian Federation
L.I. Sverzhevsky Moscow Scientific and Practical Center of Otorhinolaryngology, Moscow Healthcare DepartmentГБУЗ «Московский научно-практический центр оториноларингологии им. Л.И. Свержевского» Департамента здравоохранения г. Москвы1510201373-4981031407201414072014Copyright ©; 2013, Turovsky A.B., Karyuk Y.A., Kondrashina V.V.Copyright ©; 2013, Туровский А.Б., Карюк Ю.А., Кондрашина В.В.2013Turovsky A.B., Karyuk Y.A., Kondrashina V.V.Туровский А.Б., Карюк Ю.А., Кондрашина В.В.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/19

The paper outlines basic principles of and new approaches to antibiotic therapy for ENT and upper respiratory tract infections, from point of view of the authors, on the basis of the data available in Russian and foreign literature.

В статье с точки зрения авторов изложены основные принципы и новые подходы к антибактериальной терапии инфекций ЛОР-органов и верхних дыхательных путей на основании данных отечественной и зарубежной литературы.

upper respiratory tract infectionsENT infectionsantimicrobial agentsfluoroquinolonesmoxifloxacinинфекции верхних дыхательных путейинфекции ЛОР-органовантибактериальные препаратыфторхинолонымоксифлоксацин1. Quintiliani R., Owens R.Jr., Grant E. Clinical role of fluoroquinolones in patients with respiratory tract infections. Infect Dis Clin Pract 1999;8(Suppl 1):S28–41.Quintiliani R., Owens R.Jr., Grant E. Clinical role of fluoroquinolones in patients with respiratory tract infections. Infect Dis Clin Pract 1999;8(Suppl 1):S28–41.2. Klossek J.M., Siegert R., Nikolaidis P. et al. Sinusitis Study Group. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol 2003;117(1):43–51.Klossek J.M., Siegert R., Nikolaidis P. et al. Sinusitis Study Group. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol 2003;117(1):43–51.3. Hampel B. Clinical needs in the millennium – rhinosinusitis – the role of moxifloxacin. In: Mandell L., ed. Proceedings of the First International Moxifloxacin Symposium. Berlin:Springer-Verlag,1999:174–7.Hampel B. Clinical needs in the millennium – rhinosinusitis – the role of moxifloxacin. In: Mandell L., ed. Proceedings of the First International Moxifloxacin Symposium. Berlin:Springer-Verlag,1999:174–7.4. Дворецкий Л.И., Яковлев С.В. Ошибки в антибактериальной терапии инфекций дыхательных путей в амбулаторной практике. Лечащий врач 2003;(8):1–8.Дворецкий Л.И., Яковлев С.В. Ошибки в антибактериальной терапии инфекций дыхательных путей в амбулаторной практике. Лечащий врач 2003;(8):1–8.5. Burke Т., Villanueva C., Mariano H.Jr. et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther 1999;21(10):1664–77.Burke Т., Villanueva C., Mariano H.Jr. et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther 1999;21(10):1664–77.6. Schedletzky H., Wiedemann В., Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1999;43(Suppl B):31–7.Schedletzky H., Wiedemann В., Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1999;43(Suppl B):31–7.7. Krasemann C., Meyer J., Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001;32(Suppl 1):S51–63.Krasemann C., Meyer J., Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001;32(Suppl 1):S51–63.8. Siegert R., Gehanno P., Nikolaidis P. et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000;94(4):337–44.Siegert R., Gehanno P., Nikolaidis P. et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000;94(4):337–44.